Quest Laboratories Ltd

Quest Laboratories Limited is engaged in the business of manufacturing of pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. These formulations fall under the trademark Quest Laboratories Limited. The company produces a variety of products, comprising ethical drugs, generic drugs, and overthe-counter drugs (OTC). These products are available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids. This comprehensive approach allows the Company to address a wide range of medical needs and preferences among patients.

Open Demat Account

50years

Quest Laboratories Ltd IPO Details

Details

Total Shares OfferedOffer to PublicRetail Max (Shares)Pre Issue Promoters HoldingExchangeIssue size
44.5 LTBA14.99 L105.74 LNSE₹ 43.16 Cr
IPO Open DateClose DateLot SizeMin InvestmentIssue TypeListing Date
15 May, 2417 May, 241200 ₹ 1,11,600 Book Building - SME23 May, 24

Quest Laboratories Ltd IPO Details

Quest Laboratories Ltd IPO Dates

  • 15 May 2024

    Opening date

  • 17 May 2024

    Closing date

  • 21 May 2024

    Basis of
    Allotment

  • 22 May 2024

    Initiation of
    Refunds

  • 22 May 2024

    Credit of
    Shares

  • 23 May 2024

    Listing date

Details

SectorType
SectorPharmaceuticals - Indian - Formulations
Sub SectorNA
Issue TypeBook Building - SME

Subscription Status

*Values are in Lakhs

Investor TypeSubscription Times
QIB0x
NII0x
Retail0x
Employee0x
Total0x

Subscription Status

Investor Type

QIB

NII

Retail

Employee

Total

*Values are in Lakhs

Quest Laboratories Ltd Financial Status

Income Statement

Balance Sheet

Particulars (in Rs. Crores)FY23FY22FY21
Revenue from operations7.516.231.18
EBITDA8.066.691.57
PAT5.034.110.66
Total Assets36.0626.8512.10
Share Capital1.081.081.08
Total Borrowings6.305.244.61
Operating Activities (Net Cash)5.584.571.05
Investing Activities (Net Cash)0.090.090.09
Financing Activities (Net Cash)6.305.244.61
Net Cashflow2.501.570.42

Particulars (in Rs. Crores)

Revenue from operations

EBITDA

PAT

Total Assets

Share Capital

Total Borrowings

Operating Activities (Net Cash)

Investing Activities (Net Cash)

Financing Activities (Net Cash)

Net Cashflow

About Quest Laboratories Ltd

Quest Laboratories Limited was originally incorporated under the name Quest Laboratories Private Limited under the provisions of the Companies Act, 1956 vide Certificate of Incorporation dated June 01, 1998, issued by the Registrar of Companies Madhya Pradesh, Gwalior. Subsequently, the status of the Company was changed to public limited and the name of the Company was changed to Quest Laboratories Limited vide Special Resolution passed by the Shareholders at the Extra Ordinary General Meeting of the Company held on January 11, 2024. The fresh certificate of incorporation consequent to conversion was issued on January 23, 2024, by Assistant Registrar of Companies/ Deputy Registrar of Companies/ Registrar of Companies, Centralised Processing Centre. The Corporate Identification Number of the Company is U24232MP1998PLC012850.

India's pharmaceutical industry leads globally, renowned for affordable generic drugs and vaccines. With a 9.43% CAGR over nine years, it ranks third in production volume. Diverse segments include generics, OTC meds, bulk drugs, vaccines, biosimilars, and biologics. Notably, India houses the most USFDA-compliant manufacturing facilities and 500 API producers, capturing 8% of the global API market. This industry's growth reflects its adaptability and quality standards, ensuring accessible healthcare solutions worldwide.

Peer Comparison:

  • Quest Laboratories Ltd
  • Beta Drugs Ltd
  • Alpa Laboratories Ltd
  • Zenith Drugs Ltd

Quest Laboratories Ltd IPO Key Points

Strengths

  • Multi-product capability.
  • Revenue from Government institutions.
  • Product Portfolio.
  • Research and Development.
  • Quality assurance.

Risk

  • The company has certain outstanding litigation against it, an adverse outcome of which may adversely affect its business, reputation and results of operations.
  • Any manufacturing or quality control problems may disrupt its business operations, damage the company reputation for high quality production and expose it to potential litigation or other liabilities, which would negatively impact its business, prospects, cash flows, results of operations and financial condition.
  • The Company is reliant on the demand from the pharmaceutical industry for a significant portion of its revenue. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage its sales could have an adverse impact on the Company's business and results of operations.

Strategy

  • Expansion and upgradation of its manufacturing facility.
  • Expand its Geographical Presence.
  • Widen its product portfolio.
  • Continue to improve operating efficiencies through technology enhancements.

Quest Laboratories Ltd IPO Key Points

  • Multi-product capability.
  • Revenue from Government institutions.
  • Product Portfolio.
  • Research and Development.
  • Quality assurance.
  • The company has certain outstanding litigation against it, an adverse outcome of which may adversely affect its business, reputation and results of operations.
  • Any manufacturing or quality control problems may disrupt its business operations, damage the company reputation for high quality production and expose it to potential litigation or other liabilities, which would negatively impact its business, prospects, cash flows, results of operations and financial condition.
  • The Company is reliant on the demand from the pharmaceutical industry for a significant portion of its revenue. Any downturn in the pharmaceutical industry or an inability to increase or effectively manage its sales could have an adverse impact on the Company's business and results of operations.
  • Expansion and upgradation of its manufacturing facility.
  • Expand its Geographical Presence.
  • Widen its product portfolio.
  • Continue to improve operating efficiencies through technology enhancements.

How To Apply for Quest Laboratories Ltd Online?

Step 1:

Log in to the BlinkX stock market app and click ‘IPO’ in the Xplore section.

Step 2:

From the list of open IPOs, select the IPO you want to invest.

Step 3:

Go through the IPO details like lot size, price band, about the company, etc.

Step 4:

Click ‘Apply IPO’ to apply and enter the number of lots and bidding price along with your UPI ID.

Step 5:

Confirm your bid and accept the payment mandate sent to your UPI App for completing the IPO application.

Get your FAQs right

Quest Laboratories Ltd's IPO offers shares for up to ₹ 0 L It begins on May 15, 2024 and ends on May 17, 2024.

The price of Quest Laboratories Ltd IPO ranges between ₹93 to ₹97 per share.

The Quest Laboratories Ltd IPO opens on May 15, 2024 and closes on May 17, 2024.

The allotment for the Quest Laboratories Ltd IPO will be finalised on May 21, 2024. The shares will be listed on BSE and NSE on May 23, 2024.

The minimum lot size for Quest Laboratories Ltd IPO is 1200 shares, priced between ₹93 to ₹97 per share.

The GMP (Grey Market Premium) of Quest Laboratories Ltd IPO fluctuates based on market demand and sentiment.

To check the allotment status of Quest Laboratories Ltd IPO, visit the registrar's website, select the IPO, enter your PAN Card number, Application Number, or DP Client ID, and click 'search.'

The Quest Laboratories Ltd IPO is getting listed on the BSE and NSE. Bidding opens on May 15, 2024, and closes on May 17, 2024. The allotment is finalised on May 21, 2024.

To apply for the Quest Laboratories Ltd IPO, download the BlinkX app, complete KYC, select the IPO, enter bid details, and submit. Verify UPI payment for shares allotment.